193 related articles for article (PubMed ID: 12167561)
21. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
[TBL] [Abstract][Full Text] [Related]
22. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Kobayashi K; Urashima K; Shimada N; Chiba K
Biochem Pharmacol; 2002 Mar; 63(5):889-96. PubMed ID: 11911841
[TBL] [Abstract][Full Text] [Related]
23. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
Johnson JA; Herring VL; Wolfe MS; Relling MV
J Pharmacol Exp Ther; 2000 Sep; 294(3):1099-105. PubMed ID: 10945865
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2.
Yamamoto Y; Tasaki T; Nakamura A; Iwata H; Kazusaka A; Gonzalez FJ; Fujita S
Pharmacogenetics; 1998 Feb; 8(1):73-82. PubMed ID: 9511184
[TBL] [Abstract][Full Text] [Related]
25. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
26. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 isoforms responsible for the N-deethylation and cyclohexane-hydroxylation of NS-21.
Nakamura A; Hirota T; Morino A; Imaoka S; Funae Y; Yamamoto Y; Tasaki T; Masuda M; Kazusaka A; Fujita S
Xenobiotica; 1999 Mar; 29(3):243-52. PubMed ID: 10219965
[TBL] [Abstract][Full Text] [Related]
28. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
29. The roles of amino acid residues at positions 43 and 45 in microsomal contents and enzymatic functions of rat CYP2D1 and CYP2D2.
Narimatsu S; Imoto K; Isobe T; Kiryu K; Naito S; Hichiya H; Funae Y; Hanioka N; Yamamoto S
Biochem Biophys Res Commun; 2004 Nov; 324(2):627-33. PubMed ID: 15474473
[TBL] [Abstract][Full Text] [Related]
30. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
31. Progesterone oxidation by cytochrome P450 2D isoforms in the brain.
Hiroi T; Kishimoto W; Chow T; Imaoka S; Igarashi T; Funae Y
Endocrinology; 2001 Sep; 142(9):3901-8. PubMed ID: 11517168
[TBL] [Abstract][Full Text] [Related]
32. The Atypical Antipsychotic Lurasidone Affects Brain but Not Liver Cytochrome P450 2D (CYP2D) Activity. A Comparison with Other Novel Neuroleptics and Significance for Drug Treatment of Schizophrenia.
Danek PJ; Daniel WA
Cells; 2022 Nov; 11(21):. PubMed ID: 36359909
[TBL] [Abstract][Full Text] [Related]
33. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
Boobis AR; Murray S; Hampden CE; Davies DS
Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
[TBL] [Abstract][Full Text] [Related]
35. In vivo administration of H2 blockers, cimetidine and ranitidine, reduced the contents of the cytochrome P450IID (CYP2D) subfamily and their activities in rat liver microsomes.
Orishiki M; Matsuo Y; Nishioka M; Ichikawa Y
Int J Biochem; 1994 Jun; 26(6):751-8. PubMed ID: 8063004
[TBL] [Abstract][Full Text] [Related]
36. Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19.
Hichiya H; Kuramoto S; Yamamoto S; Shinoda S; Hanioka N; Narimatsu S; Asaoka K; Miyata A; Iwata S; Nomoto M; Satoh T; Kiryu K; Ueda N; Naito S; Tucker GT; Ellis SW
Biochem Pharmacol; 2004 Jul; 68(1):165-75. PubMed ID: 15183128
[TBL] [Abstract][Full Text] [Related]
37. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
38. Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes.
Cooke BR; Bligh SW; Cybulski ZR; Ioannides C; Hall M
Drug Metab Dispos; 2012 Jan; 40(1):70-5. PubMed ID: 21976620
[TBL] [Abstract][Full Text] [Related]
39. Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.
Smith G; Modi S; Pillai I; Lian LY; Sutcliffe MJ; Pritchard MP; Friedberg T; Roberts GC; Wolf CR
Biochem J; 1998 May; 331 ( Pt 3)(Pt 3):783-92. PubMed ID: 9560305
[TBL] [Abstract][Full Text] [Related]
40. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison.
Löfgren S; Hagbjörk AL; Ekman S; Fransson-Steen R; Terelius Y
Xenobiotica; 2004 Sep; 34(9):811-34. PubMed ID: 15742976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
